BRUSSELS (dpa-AFX) - Switzerland-based healthcare business Lonza Group AG
(LZAGF) on Tuesday confirmed its outlook for 2024 at flat sales growth in CER
and Core EBITDA margin of high 20s. Sales in the second half of 2024 are
expected to be solid, reflecting the timing of batch releases.

In its quarterly qualitative update, Lonza had reported a softer first quarter,
with performance across the first half expected to align with the full-year 2024
trajectory.

The company also said that its key growth projects were progressing in line with
plan. Operations are expected to commence at the large-scale Mammalian drug
substance and highly potent API facilities in Visp in the fourth quarter of
2024. Construction is also on track at the large-scale commercial drug product
facility in Stein.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX